Every 10-Q that Arrowhead Research Corporation (ARWR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ARWR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARWR filings page.
Arrowhead Pharmaceuticals, Inc. reported a sharp swing to a loss for the quarter ended March 31, 2026. Revenue was $73.7 million, down from $542.7 million a year earlier, when it booked large milestone payments, leading to a net loss attributable to Arrowhead of $132.7 million versus net income of $370.4 million in the prior-year quarter.
For the first six months, revenue totaled $337.8 million and the net loss was $101.9 million. Cash, cash equivalents and restricted cash were $188.5 million, with available-for-sale securities of $1.60 billion, supporting ongoing R&D spending of $350.5 million over six months and a growing collaboration portfolio with Sarepta, Novartis and Sanofi.
Arrowhead Pharmaceuticals, Inc. reported a sharp turnaround for the quarter ended December 31, 2025, with revenue of $264.0 million driven mainly by collaboration payments, compared with $2.5 million a year earlier. Net income attributable to the company was $30.8 million, versus a loss of $173.1 million.
Results were boosted by $229.5 million in revenue from Sarepta milestones and research, and $34.2 million from a new Novartis collaboration. Arrowhead ended the quarter with $201.6 million in cash, cash equivalents and restricted cash and $715.0 million in available-for-sale securities. The FDA approved REDEMPLO for Familial Chylomicronemia Syndrome, giving the company its first commercial RNAi product.